EVIDENCE PROFILE / PUBLISHED
Modified GRF (1-29)
Modified GRF (1-29) refers to short GHRH analogues with substitutions intended to resist degradation. The commercial phrase 'CJC-1295 without DAC' is imprecise and does not make it original long-acting CJC-1295. Human studies of GHRH(1-29) and related analogues demonstrate acute GH biomarker responses, not broad clinical outcomes.
Evidence at a glance
- Human
- Not rated
- Animal/cell
- Not rated
- Approved medicine
- None foundScope: the sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. Research examines GHRH-receptor activation and short-lived growth-hormone release.
Identity
Modified GRF (1-29) refers to short GHRH analogues with substitutions intended to resist degradation. The commercial phrase 'CJC-1295 without DAC' is imprecise and does not make it original long-acting CJC-1295.
Biological mechanism or research interest
Research examines GHRH-receptor activation and short-lived growth-hormone release.
Verified approved human uses
No approved use for a material called modified GRF (1-29) was verified in the reviewed sources.
Investigational human evidence
Human studies of GHRH(1-29) and related analogues demonstrate acute GH biomarker responses, not broad clinical outcomes.
Popular claims versus demonstrated findings
Body-composition, recovery, sleep, and anti-aging claims exceed the biomarker evidence.
Human versus animal or cell evidence
Analogue stability and potency work includes in-vitro and animal comparisons.
Limitations and known risks
Exact substitutions, amidation, purity, endocrine effects, glucose effects, and long-term safety depend on the actual molecule and remain unresolved.
